• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 29, 2023

View Archived Issues
C. auris illustration

Scientists report new insights into what makes Candida auris such a sticky problem

The fungus Candida auris has become an urgent clinical problem at a shocking speed. It was not even mentioned in the U.S. CDC’s 2013 reports on antimicrobial threats, but was one of five pathogens on the agency’s 2019 top-tier Urgent Threat List. Read More

NOTCH1 rearrangements as targetable feature of reninoma tumors

Reninomas are rare renin-secreting kidney tumors, resulting from a neoplastic expansion of juxtaglomerular cells of the kidney, which are cells that regulate blood pressure via the secretion of renin. Based on previous research that has proposed a central role for NOTCH1 signaling in the regulation of renin secretion by juxtaglomerular cells, researchers from Wellcome Sanger Institute, University of Cambridge, and affiliated organizations aimed to investigate the role of NOTCH1 in reninoma. Read More
Antibodies block virus from cell

New computationally designed antigen targeting multiple sarbecoviruses shows in vivo efficacy

Viruses of the Betacoronavirus genus that bind to angiotensin-converting enzyme 2 (ACE2) are the coronaviruses posing the most significant pandemic risk. Sarbecoviruses of this genus caused the severe acute respiratory syndrome (SARS) epidemic and the SARS-CoV-2 pandemic. Therefore, new vaccines with broader protection from ACE2-binding sarbecoviruses and emerging variants of concern are urgently needed. Read More
Illustration of blood vessel that isn't clotting due to hemophilia

FDA awards orphan drug designation to Baudax’s TI-168 for hemophilia A with inhibitors

Baudax Bio Inc.’s lead clinical candidate, TI-168, has been awarded U.S. orphan drug designation by the FDA for the treatment of hemophilia A with inhibitors. TI-168 is a next-generation, factor VIII (FVIII)-specific regulatory T-cell (Treg) therapy designed to address hemophilia A in patients with FVIII inhibitors. Read More

Firefly Bio patents new antibody-drug conjugates

Researchers at Firefly Bio Inc. have prepared antibody-drug conjugates (ADCs) comprising monoclonal antibodies targeting HER2 covalently linked to stimulator of interferon genes protein (STING; TMEM173) agonists through a linker. They are reported to be useful for the treatment of cancer, autoimmune disease, inflammation and infections. Read More
Lyme disease bacteria, Borrelia burgdorferi, transmitted by Ixodes tick, 3D illustration

Applying an mRNA-lipid nanoparticle platform to develop vaccine against Lyme disease

Lyme disease, caused by the bacteria Borrelia burgdorferi and transmitted by Ixodes ticks, is expanding in many countries, posing a significant global health concern. The outer surface protein A (OspA) of B. burgdorferi is currently the most promising target for vaccine development, primarily because of its broad conservation among different bacterial strains that cause the disease. In a recent publication, researchers from the University of Pennsylvania and collaborators proposed using a lipid nanoparticle-encapsulated nucleoside-modified mRNA (mRNA-LNP) platform, similar to that of clinical vaccines against SARS-CoV-2, to develop a vaccine against Lyme disease. Read More
Test-tubes_dropper2.png

FHND-5071, a novel RET kinase inhibitor with promising preclinical metabolism and PK characteristics

Researchers from Jiangsu Chia Tai Fenghai Pharmaceutical Co. Ltd. and affiliated organizations have published preclinical data for the novel rearranged during transfection (RET) kinase inhibitor, FHND-5071. Read More

Flare Therapeutics divulges new PPARγ inverse agonists for treatment of bladder cancer

Flare Therapeutics Inc. has patented peroxisome proliferator-activated receptor γ (PPARγ, PPARG) inverse agonists reported to be useful for the treatment of bladder cancer. Read More

Baruch S Blumberg Institute patent details new compounds for treatment of yellow fever virus infections

Research at Baruch S Blumberg Institute has led to the discovery of new diazepine derivatives targeting yellow fever virus nonstructural protein 4B (NS4B) for the treatment of yellow fever virus infections. Read More
Drug research

Quris and Merck KGaA extend collaboration using BioAI drug safety platform

Quris Technologies Ltd. (Quris-AI) and Merck KGaA have extended their collaboration after a successful initial preclinical study of Quris-AI’s BioAI drug safety platform. Read More

Roche describes new LpxH inhibitors for bacterial infections

Benzamide compounds acting as UDP-2,3-diacylglucosamine hydrolase (LpxH) (bacterial) inhibitors have been reported in an F. Hoffmann-La Roche Ltd. patent to be useful for the treatment of gram-negative bacterial infections, particularly Klebsiella pneumoniae and Escherichia coli infections. Read More

Shanghai Zhigen Pharmaceutical Technology reports aminoketone compounds for treatment of depression

Shanghai Zhigen Pharmaceutical Technology Co. Ltd. has identified aminoketone compounds with improved chemical stability that are potentially useful for the treatment of depression, post-traumatic stress, obsessive-compulsive disorder, pain and anxiety disorders. Read More
Virus research

Modex Therapeutics awarded BARDA contract for multispecific antibodies against viral infectious disease threats

Modex Therapeutics Inc. has been awarded a contract from the Biomedical Advanced Research and Development Authority (BARDA) to advance a platform and specific candidates designed to address a range of public health threats in viral infectious diseases. Read More

Other news to note for Sept. 29, 2023

Additional early-stage research and drug discovery news in brief, from: Kura, Pharmnovo. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 5, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 5, 2025.
  • White puzzle pieces on blue background

    Highridge sells bone healing business to Avista

    BioWorld MedTech
    In the midst of June’s peak wedding season, Highridge Medical LLC called it splitsville – selling its bone healing division to Avista Healthcare Partners. The...
  • DNA mutations or genetic disorder concept art

    Regenxbio’s Duchenne gene therapy data positive as shares falter

    BioWorld
    Regenxbio Inc.’s gene therapy in treating Duchenne muscular dystrophy (DMD) produced positive initial phase I/II results from its first five patients. However,...
  • Pill with British pound sign

    Pharma execs speak out: UK pricing rebates scare investors

    BioWorld
    The row between pharma companies and the U.K. government over rebates has intensified, with the Association of the British Pharmaceutical Industry calling up its...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe